CN1324234A - 果糖胺氧化酶,拮抗剂和抑制剂 - Google Patents
果糖胺氧化酶,拮抗剂和抑制剂 Download PDFInfo
- Publication number
- CN1324234A CN1324234A CN99811149A CN99811149A CN1324234A CN 1324234 A CN1324234 A CN 1324234A CN 99811149 A CN99811149 A CN 99811149A CN 99811149 A CN99811149 A CN 99811149A CN 1324234 A CN1324234 A CN 1324234A
- Authority
- CN
- China
- Prior art keywords
- patient
- fructosamine oxidase
- treatment
- inhibitor
- diabetics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Abstract
Description
Claims (35)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ332084 | 1998-09-25 | ||
NZ33208498 | 1998-09-25 | ||
NZ332079 | 1998-09-28 | ||
NZ33207998 | 1998-09-28 | ||
NZ33447199 | 1999-03-03 | ||
NZ334471 | 1999-03-03 | ||
NZ337042 | 1999-08-03 | ||
NZ33704299 | 1999-08-03 | ||
US09/671,967 US6348465B1 (en) | 1998-09-25 | 2000-09-27 | Fructosamine oxidase: antagonists and inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1324234A true CN1324234A (zh) | 2001-11-28 |
Family
ID=27532651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99811149A Pending CN1324234A (zh) | 1998-09-25 | 1999-09-24 | 果糖胺氧化酶,拮抗剂和抑制剂 |
Country Status (4)
Country | Link |
---|---|
US (5) | US6348465B1 (zh) |
EP (1) | EP1115389B1 (zh) |
CN (1) | CN1324234A (zh) |
WO (1) | WO2000018392A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112656791A (zh) * | 2021-02-01 | 2021-04-16 | 洪楠方 | 一种治疗枫糖尿病的化合物 |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002525106A (ja) | 1998-09-25 | 2002-08-13 | グリコックス コーポレイション リミティド | フルクトサミンオキシダーゼアッセイ:方法及び材料 |
EP1115389B1 (en) | 1998-09-25 | 2014-03-12 | PhilERA New Zealand Limited | Fructosamine oxidase: antagonists and inhibitors |
US20030130185A1 (en) * | 2000-09-29 | 2003-07-10 | David Bar-Or | Metal-binding compounds and uses therefor |
US20030158111A1 (en) * | 1999-10-01 | 2003-08-21 | David Bar-Or | Methods and products for oral care |
US7592304B2 (en) * | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
AU2000276021B2 (en) * | 2000-08-18 | 2006-04-06 | The General Hospital Corporation | Method for the identification of agents that inhibit or promote cataracts and uses thereof |
FR2815541B1 (fr) * | 2000-10-24 | 2008-02-29 | Lipha | Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique |
US20040038861A1 (en) * | 2001-11-26 | 2004-02-26 | Cooper Garth J. S. | Methods and compositions for normalizing lipid levels in mammalian tissues |
CA2468083C (en) * | 2001-12-06 | 2016-02-23 | Fibrogen, Inc. | Use of heterocyclic carboxamides to treat anemia |
AU2003303666A1 (en) * | 2002-01-29 | 2004-08-13 | Protemix Discovery Limited | Suppression of cytotoxic protein conformers |
WO2003077901A1 (en) | 2002-03-08 | 2003-09-25 | Protemix Corporation Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
AU2003258909B2 (en) * | 2002-08-20 | 2010-07-08 | Philera New Zealand Limited | Dosage forms and related therapies |
AU2004298393A1 (en) * | 2003-12-19 | 2005-06-30 | Protemix Corporation Limited | Copper antagonist compounds |
KR20070004730A (ko) * | 2004-02-17 | 2007-01-09 | 다이나미스 테라퓨틱스, 인코포레이티드 | 프룩토스아민 3 키나아제 및 콜라겐 및 엘라스틴의 형성 |
CA2568134A1 (en) * | 2004-05-24 | 2005-12-08 | New York University | Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux |
DK1778618T3 (da) | 2004-07-19 | 2014-03-10 | Philera New Zealand Ltd | Syntese af triethylentetraminer |
WO2006104400A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
WO2006104399A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
WO2006104398A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
WO2006104401A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
AU2006240568A1 (en) * | 2005-04-25 | 2006-11-02 | Philera New Zealand Limited | Copper regulation evaluation and therapy |
CN101217934B (zh) * | 2005-05-23 | 2013-01-02 | 陶氏康宁公司 | 含糖-硅氧烷共聚物的个人护理组合物 |
CA2632697C (en) * | 2005-11-09 | 2016-01-05 | Protemix Corporation Limited | Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits |
WO2007097951A2 (en) * | 2006-02-17 | 2007-08-30 | Nitromed, Inc. | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
CA2644488A1 (en) * | 2006-03-24 | 2007-10-04 | National Research Council Of Canada | Anti-diabetic cataract compounds and their uses |
US7834050B2 (en) * | 2006-03-29 | 2010-11-16 | Duke University | Small molecule insulin mimetics absent quinones |
US20090306081A1 (en) * | 2006-05-16 | 2009-12-10 | Letts L Gordon | Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds |
US11759477B2 (en) | 2007-02-26 | 2023-09-19 | Heartbeet Ltd. | Compositions of nitrates and methods of use thereof |
US10842813B2 (en) | 2007-02-26 | 2020-11-24 | Heartbeet Ltd | Compositions of nitrates and methods of use thereof |
DK2124638T3 (en) | 2007-02-26 | 2017-03-20 | Heartbeet Ltd | COMPOSITION INCREASING PERFORMANCE AND USING IT |
US10821132B2 (en) | 2007-02-26 | 2020-11-03 | Heartbeet Ltd | Compositions of nitrates and methods of use thereof |
US10098857B2 (en) | 2008-10-10 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds |
US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
JP6989262B2 (ja) | 2014-10-27 | 2022-01-05 | アセコー インコーポレイテッド | 皮下外来患者管理 |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
JP6858751B2 (ja) | 2015-08-20 | 2021-04-14 | アセコー インコーポレイテッド | 糖尿病管理療法アドバイザ |
WO2017049529A1 (en) | 2015-09-24 | 2017-03-30 | Innolife Co., Ltd. | A pharmaceutical composition comprising a copper chelating tetramine and the use thereof |
US11331288B2 (en) | 2017-09-14 | 2022-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Conditioning irradiated tissue for increasing vascularity |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
WO2021184097A1 (pt) | 2020-03-18 | 2021-09-23 | Faculdades Católicas | Compostos n-acil-hidrazônicos, uso no tratamento de agregopatias degenerativas amiloides e não-amiloides, e composição farmacêutica |
WO2024047474A1 (en) * | 2022-08-27 | 2024-03-07 | Biophore India Pharmaceuticals Pvt. Ltd | Trientine liquid dosage forms |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3791988A (en) * | 1972-03-23 | 1974-02-12 | Hoffmann La Roche | Diagnostic test for glucose |
PL105793B1 (pl) | 1977-11-24 | 1979-10-31 | Sposob otrzymywania soli kwasow dwukarboksylowych i poliamin | |
IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4323558A (en) * | 1979-09-10 | 1982-04-06 | Nelson Research & Development Co. | Topical trien containing pharmaceutical compositions and methods of use |
US4371374A (en) | 1980-11-17 | 1983-02-01 | The Rockefeller University | Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine |
JPS57144215A (en) * | 1981-03-02 | 1982-09-06 | Nippon Nousan Kogyo Kk | Composition for improving lipometabolism |
DE3217071A1 (de) * | 1982-05-06 | 1983-11-10 | Rüdiger Dr. 6365 Rosbach Gröning | Arzneimittel fuer die perorale applikation mit verbesserter biologischer verfuegbarkeit der wirkstoffe |
US4758583A (en) | 1984-03-19 | 1988-07-19 | The Rockefeller University | Method and agents for inhibiting protein aging |
US4665192A (en) | 1984-03-19 | 1987-05-12 | The Rockefeller University | 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole |
US5852009A (en) * | 1984-03-19 | 1998-12-22 | The Rockefeller University | Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon |
WO1987005505A1 (en) * | 1986-03-21 | 1987-09-24 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
CH666814A5 (it) * | 1986-07-24 | 1988-08-31 | Inpharzam Int Sa | Composizione farmaceutica idrosolubile contenente n-acetil-cisteina. |
CH667590A5 (it) * | 1986-07-24 | 1988-10-31 | Inpharzam Int Sa | Composizione farmaceutica effervescente idrosolubile contenente n-acetil-cisteina. . |
US4866090A (en) | 1988-01-07 | 1989-09-12 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
EP0331014A3 (de) * | 1988-03-02 | 1991-10-23 | THERA - Patent Verwaltungs-GmbH | Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe |
JPH01294631A (ja) * | 1988-05-19 | 1989-11-28 | Sanwa Kagaku Kenkyusho Co Ltd | 糖尿性疾患治療予防剤及び飲食、し好物 |
US5077313A (en) * | 1988-11-25 | 1991-12-31 | Gert Lubec | Process for inhibiting pathological collagen cross-linking in diabetes patients |
CA2026686A1 (en) * | 1989-10-30 | 1991-05-01 | Werner Tschollar | Method for preventing onset of type ii diabetes employing an ace inhibitor |
US5447728A (en) * | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
DE69221501T2 (de) * | 1991-12-06 | 1998-03-12 | North Shore Univ Hospital | Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen |
US5246970A (en) * | 1991-12-16 | 1993-09-21 | Washington University | Method of inhibiting nitric oxide formation |
JP3157622B2 (ja) * | 1992-06-05 | 2001-04-16 | 株式会社ミツカングループ本社 | フルクトシルアミンデグリカーゼ、その製造法及び該酵素を用いたアマドリ化合物の定量方法 |
JPH07118148A (ja) | 1993-10-26 | 1995-05-09 | Tsumura & Co | 肝癌予防剤 |
US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
AU1447095A (en) * | 1993-12-30 | 1995-07-17 | Arcturus Pharmaceutical Corporation | Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways |
US5854271A (en) * | 1994-05-02 | 1998-12-29 | Cytos Pharmaceuticals, L.L.C. | Effective method for the amelioration and prevention of tissue and cellular damage |
WO1996012483A1 (en) | 1994-10-25 | 1996-05-02 | Washington University | Method of inhibiting nitric oxide formation |
CA2178541C (en) * | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5906996A (en) * | 1996-08-21 | 1999-05-25 | Murphy; Michael A. | Tetramine treatment of neurological disorders |
EP1007048A4 (en) | 1997-03-11 | 2004-09-22 | Gen Hospital Corp | IDENTIFICATION OF AGENTS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
GB9720372D0 (zh) * | 1997-07-09 | 1997-11-26 | Reckitt & Colman France | |
US5834032A (en) * | 1997-08-11 | 1998-11-10 | Song; Moon K. | Compositions and methods for treating diabetes |
US6576672B1 (en) * | 1998-08-21 | 2003-06-10 | Michael A. Murphy | Polyamine treatment of neurological disorders |
US20050085555A1 (en) * | 1997-08-21 | 2005-04-21 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
US20030013772A1 (en) * | 2000-02-23 | 2003-01-16 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
US5980914A (en) * | 1997-08-22 | 1999-11-09 | P.N. Gerolymatos S.A. | Clioquinol for the treatment of Parkinson's disease |
US6821954B2 (en) * | 1997-09-18 | 2004-11-23 | Auckland Uniservices Limited | Compounds and uses thereof in treating bone disorders |
US5972985A (en) * | 1997-11-03 | 1999-10-26 | Cytos Pharmaceuticals, Llc | Histidine containing nutriceutical compositions |
MXPA00007585A (es) * | 1998-02-04 | 2002-10-17 | Euro Celtique Sa | Semicarbazidas substituidas y el uso de las mismas. |
US6323218B1 (en) | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
US6147070A (en) * | 1998-06-05 | 2000-11-14 | Facchini; Francesco | Methods and compositions for controlling iron stores to treat and cure disease states |
SI1107795T1 (en) | 1998-09-04 | 2003-06-30 | The Regents Of The University Of Michigan | Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis |
EP1115389B1 (en) | 1998-09-25 | 2014-03-12 | PhilERA New Zealand Limited | Fructosamine oxidase: antagonists and inhibitors |
JP2002525106A (ja) * | 1998-09-25 | 2002-08-13 | グリコックス コーポレイション リミティド | フルクトサミンオキシダーゼアッセイ:方法及び材料 |
JP2000204037A (ja) | 1999-01-12 | 2000-07-25 | Tsumura & Co | 筋萎縮性側索硬化症治療薬 |
US6309380B1 (en) * | 1999-01-27 | 2001-10-30 | Marian L. Larson | Drug delivery via conformal film |
US20030166561A1 (en) * | 1999-06-18 | 2003-09-04 | Cooper Garth J. S. | Peptide |
JP2003503019A (ja) | 1999-06-18 | 2003-01-28 | プロテミックス コーポレイション リミティド | プレプチン機能を有するペプチド |
CA2405512C (en) * | 2000-05-11 | 2008-02-12 | The Procter & Gamble Company | Highly concentrated fabric softener compositions and articles containing such compositions |
US7754765B2 (en) * | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
EP1370254B1 (en) | 2000-12-01 | 2008-01-16 | Radical Vision Therapeutics Inc. | Copper chelators for treating ocular inflammation |
US6585782B2 (en) | 2001-02-27 | 2003-07-01 | Everlight Usa, Inc. | Mixtures of reactive dyes and their use |
CA2442674A1 (en) | 2001-03-30 | 2002-10-10 | Garth J. S. Cooper | Phosphoprotein target for insulin and its antagonists |
EP1417055A4 (en) | 2001-07-19 | 2007-09-26 | Dmi Biosciences Inc | USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C |
US20040038861A1 (en) * | 2001-11-26 | 2004-02-26 | Cooper Garth J. S. | Methods and compositions for normalizing lipid levels in mammalian tissues |
CA2471833A1 (en) | 2001-11-26 | 2003-06-05 | Protemix Corporation Limited | Methods of compositions for normalizing lipid levels in mammalian tissues |
WO2003062275A1 (en) | 2002-01-18 | 2003-07-31 | Protemix Corporation Limited | Glycoisoforms of adiponectin and uses thereof |
WO2003062404A1 (en) * | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
AU2003303666A1 (en) | 2002-01-29 | 2004-08-13 | Protemix Discovery Limited | Suppression of cytotoxic protein conformers |
US20050074756A1 (en) * | 2002-03-01 | 2005-04-07 | Cooper Garth James Smith | FALP proteins |
WO2003075910A1 (en) | 2002-03-08 | 2003-09-18 | Protemix Corporation Limited | Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure |
WO2003077901A1 (en) | 2002-03-08 | 2003-09-25 | Protemix Corporation Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
DE60208544T2 (de) | 2002-04-03 | 2006-11-16 | Puleva Biotech, S.A. | Natürliche phenolische produkte und deren derivate zum schutz vor neurodegenerativen erkrankungen |
US6793053B2 (en) | 2002-04-05 | 2004-09-21 | Sonnax Industries, Inc. | Torque converter clutch regulator valve assembly |
AU2003222533A1 (en) | 2002-04-29 | 2003-11-17 | Protemix Corporation Limited | Proteins with deglycating activities and methods of using same |
EP1531827A4 (en) | 2002-05-24 | 2009-07-08 | Univ Michigan | COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES |
CA2390264C (en) * | 2002-07-02 | 2011-02-08 | Edward Garnet Hunter | Method of manufacturing a skateboard deck |
GEP20074270B (en) * | 2002-07-23 | 2007-12-25 | Univ Michigan | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
US7189865B2 (en) * | 2002-07-23 | 2007-03-13 | Attenuon, Llc | Thiomolybdate analogues and uses thereof |
US20040142393A1 (en) * | 2002-08-01 | 2004-07-22 | Cooper Garth James Smith | Methods of use of compounds with preptin function |
CN1684705A (zh) | 2002-08-01 | 2005-10-19 | 普罗特米克斯公司 | 使用具有preptin功能的化合物的方法 |
CA2494305A1 (en) | 2002-08-01 | 2004-02-12 | Auckland Uniservices Limited | Preptin methods of use |
AU2003258909B2 (en) | 2002-08-20 | 2010-07-08 | Philera New Zealand Limited | Dosage forms and related therapies |
WO2004017957A1 (en) | 2002-08-20 | 2004-03-04 | Protemix Corporation Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
KR100534461B1 (ko) * | 2002-11-11 | 2005-12-07 | 황준호 | 골프화 |
AU2003285686A1 (en) | 2002-12-23 | 2004-07-14 | Protemix Corporation Limited | Glycoisoforms of adiponectin and uses thereof |
US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
CA2517755A1 (en) | 2003-03-21 | 2004-09-30 | Palumed Sa | Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications |
US20070037848A1 (en) | 2003-04-03 | 2007-02-15 | Masters Colin L | Treatment of neurological conditions |
WO2004100884A2 (en) * | 2003-05-07 | 2004-11-25 | Dmi Biosciences, Inc. | Oral care methods and products |
WO2005002643A2 (en) * | 2003-06-24 | 2005-01-13 | Johns Hopkins University | Method and products for delivering biological molecules to cells using multicomponent nanostructures |
US7176239B2 (en) * | 2003-07-11 | 2007-02-13 | Suming Wang | Methods and compositions for treatment of Ataxia-telangeictasia |
CN1898260A (zh) | 2003-10-28 | 2007-01-17 | 普罗特米克斯发现有限公司 | 具有抗肥胖活性的肽及其它相关应用 |
AU2004298393A1 (en) | 2003-12-19 | 2005-06-30 | Protemix Corporation Limited | Copper antagonist compounds |
-
1999
- 1999-09-24 EP EP99946470.4A patent/EP1115389B1/en not_active Expired - Lifetime
- 1999-09-24 CN CN99811149A patent/CN1324234A/zh active Pending
- 1999-09-24 WO PCT/NZ1999/000161 patent/WO2000018392A1/en active Application Filing
-
2000
- 2000-09-27 US US09/671,967 patent/US6348465B1/en not_active Expired - Lifetime
-
2001
- 2001-10-10 US US09/975,751 patent/US6610693B2/en not_active Expired - Lifetime
-
2002
- 2002-08-23 US US10/226,685 patent/US6897243B2/en not_active Expired - Lifetime
-
2004
- 2004-12-28 US US11/023,827 patent/US7459446B2/en not_active Expired - Lifetime
-
2007
- 2007-10-31 US US11/981,861 patent/US7928094B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112656791A (zh) * | 2021-02-01 | 2021-04-16 | 洪楠方 | 一种治疗枫糖尿病的化合物 |
Also Published As
Publication number | Publication date |
---|---|
EP1115389A1 (en) | 2001-07-18 |
US7928094B2 (en) | 2011-04-19 |
US20080108705A1 (en) | 2008-05-08 |
EP1115389A4 (en) | 2006-04-12 |
EP1115389B1 (en) | 2014-03-12 |
US6897243B2 (en) | 2005-05-24 |
US20030045506A1 (en) | 2003-03-06 |
US7459446B2 (en) | 2008-12-02 |
WO2000018392A1 (en) | 2000-04-06 |
US20050159489A1 (en) | 2005-07-21 |
US6348465B1 (en) | 2002-02-19 |
US20020156020A1 (en) | 2002-10-24 |
US6610693B2 (en) | 2003-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1324234A (zh) | 果糖胺氧化酶,拮抗剂和抑制剂 | |
JPH07503713A (ja) | 蛋白質の高度グリコシル化阻害剤として有用なアミノ酸 | |
JPS62142114A (ja) | メイラード反応阻害剤 | |
US20190240292A1 (en) | Methods of administering hepcidin | |
JP2002542191A (ja) | グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物 | |
JP2023022318A (ja) | ペプチドwkdeagkplvkを含む組成物 | |
US20040038867A1 (en) | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus | |
KR920002935B1 (ko) | 맥관 형성 저해제 | |
EP3158995B1 (en) | Meglumine for reducing high triglyceride levels | |
JP6240447B2 (ja) | エラスチン産生促進剤 | |
JP5916051B2 (ja) | 抗炎症剤および抗炎症剤の製造方法 | |
US8138227B2 (en) | Method for inhibiting or reversing non-enzymatic glycation | |
JPH0761924A (ja) | 腸内細菌の血中転移を抑制する輸液製剤 | |
CA2344690C (en) | Fructosamine oxidase: antagonists and inhibitors | |
SE457958B (sv) | Vattenloeslig hemin-arginat eller hemin-lysinat-foerening, foerfarande foer framstaellning daerav samt anvaendning daerav foer tillverkning av medicinska kompositioner | |
WO2004096843A1 (ja) | 消化器官吸収性ポリペプチド | |
TW200808338A (en) | Vasodilator and functional food | |
NZ539272A (en) | Using an antagonist or an inhibitor of Fructosamine oxidase to reduce minimising the effects of macrovascular and microvascular damage in a diabetic patient | |
JP2002515031A (ja) | タンパク質グリコシル化の阻害および血管疾患の予防 | |
TW202135852A (zh) | 用於治療肥胖症之使用升糖素和glp-1共促效劑之組合療法 | |
EP4087596A1 (en) | Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes | |
WO2006132245A1 (ja) | 腫瘍増殖抑制剤 | |
JPH01131120A (ja) | 新規の低血糖剤及び成長促進剤 | |
JPWO2004073740A1 (ja) | 組織内アンジオテンシンii産生亢進制御剤並びに動脈硬化症、心・脳血管疾患及び/若しくは糖尿病合併症の発症予防又は治療剤 | |
WO2013110471A1 (de) | Mittel zur endotoxin-detoxifikation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: PROLON TELMIX CO., LTD. Free format text: FORMER OWNER: GLYCOX CORP., LTD. Effective date: 20030709 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030709 Address after: Oakland, New Zealand Applicant after: The general Taimikesi Co. Ltd. Address before: Oakland, New Zealand Applicant before: Glycox Corp. Ltd. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1071783 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20011128 |